Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
Abnormal hepatic function evidenced by ALT and AST value \>2.5 UNL
Subjects with any other malignant disease that can affect the bone.
Subjects with any other non malignant disease that can jeopardize the evaluation of the primary objectives of this trial (severe osteoporosis) or that do not aloud perform the trial evaluations.
Known hypersensibility to zoledronic acid or other bisphosphonates.
Subjects that in the investigator's opinion can not cooperate with the protocol.
Clareo Health | Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
